{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:20:29Z","timestamp":1777652429392,"version":"3.51.4"},"reference-count":114,"publisher":"Elsevier","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.035","type":"book-chapter","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T19:43:57Z","timestamp":1747770237000},"source":"Crossref","is-referenced-by-count":2,"title":["Contribution of cellular immune dysregulation to myasthenia gravis pathology"],"prefix":"10.1016","author":[{"given":"Alexandra C.","family":"Bayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.035_bib1","series-title":"Cellular and molecular immunology","first-page":"587","author":"Abbas","year":"2022"},{"key":"10.1016\/bs.irn.2025.04.035_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"issue":"19","key":"10.1016\/bs.irn.2025.04.035_bib3","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib4","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurology\u00ae neuroimmunology & neuroinflammation"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-5699(99)01553-4","article-title":"Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis","volume":"21","author":"Balasa","year":"2000","journal-title":"Immunology Today"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.035_bib7","first-page":"54","article-title":"Circulating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: A flow cytometry study","volume":"19","author":"Battaglia","year":"2005","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1074-7613(00)00080-7","article-title":"Impact of negative selection on the T cell repertoire reactive to a self-peptide: A large fraction of T cell clones escapes clonal deletion","volume":"13","author":"Bouneaud","year":"2000","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-016-0160-z","article-title":"T cell exhaustion: From pathophysiological basics to tumor immunotherapy","volume":"15","author":"Catakovic","year":"2017","journal-title":"Cell Communication and Signaling"},{"key":"10.1016\/bs.irn.2025.04.035_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4(+) T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"Cebi","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-019-0203-y","article-title":"Metabolic coordination of T cell quiescence and activation","volume":"20","author":"Chapman","year":"2019","journal-title":"Nature Reviews. Immunology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.035_bib13","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.4049\/jimmunol.136.7.2437","article-title":"Immunotherapy for myasthenia gravis: A murine model","volume":"136","author":"Christadoss","year":"1986","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib15","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.035_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib18","first-page":"289","article-title":"IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T cells","volume":"5","author":"Duke","year":"1986","journal-title":"Lymphokine Research"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-00454-2","article-title":"Rethinking peripheral T cell tolerance: Checkpoints across a T cell\u2019s journey","volume":"21","author":"ElTanbouly","year":"2020","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.irn.2025.04.035_bib21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/j.0105-2896.2006.00348.x","article-title":"Central tolerance: Good but imperfect","volume":"209","author":"Gallegos","year":"2006","journal-title":"Immunological Reviews"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nature Reviews. Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"Journal of Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib25","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1073\/pnas.93.6.2264","article-title":"Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires","volume":"93","author":"Goodnow","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2025.04.035_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: Role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.035_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both treg cells and Tconv cells are defective in the myasthenia gravis thymus: Roles of IL-17 and TNF-\u03b1","volume":"52","author":"Gradolatto","year":"2014","journal-title":"Journal of Autoimmunity"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.035_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-Lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/ni1076","article-title":"Receptor editing is the main mechanism of B cell tolerance toward membrane antigens","volume":"5","author":"Halverson","year":"2004","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib32","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028621","article-title":"Cytokines, transcription factors, and the initiation of T-cell development","volume":"10","author":"Hosokawa","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2014","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/bs.irn.2025.04.035_bib34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02299-y","article-title":"Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature","volume":"141","author":"Ingelfinger","year":"2021","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.irn.2025.04.035_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136471","article-title":"Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses","author":"Jiang","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib37","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.6.3152","article-title":"Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis","volume":"152","author":"Kaul","year":"1994","journal-title":"The Journal of Immunology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.035_bib38","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2013","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"624","key":"10.1016\/bs.irn.2025.04.035_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk2132","article-title":"Functional impairment of CD19(+)CD24(hi)CD38(hi) B cells in neuromyelitis optica spectrum disorder is restored by B cell depletion therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2025.04.035_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2017.03.003","article-title":"CD4(+) FoxP3(+) T regulatory cell subsets in myasthenia gravis patients","volume":"179","author":"Kohler","year":"2017","journal-title":"Clinical Immunology (Orlando, Fla.)"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.035_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/acn3.311","article-title":"Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis","volume":"3","author":"Lee","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2025.04.035_bib43","article-title":"Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures","author":"Li","year":"2025","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2025.04.035_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577279","article-title":"Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis","volume":"345","author":"Li","year":"2020","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib45","article-title":"Regulatory B cells are decreased and functionally impaired in myasthenia gravis patients","volume":"13","author":"Lin","year":"2022","journal-title":"Frontiers in Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib46","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.44.4.728","article-title":"Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis","volume":"44","author":"Link","year":"1994","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0000000000012471","article-title":"Antibodies to LRP4 and agrin are pathogenic in myasthenia gravis: At the junction where it happens","volume":"97","author":"Lisak","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.035_bib48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/1074-7613(95)90170-1","article-title":"Low avidity recognition of self-antigen by T cells permits escape from central tolerance","author":"Liu","year":"1995","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib49","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4049\/jimmunol.0802046","article-title":"Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients","volume":"183","author":"Luther","year":"2009","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","article-title":"Th17 cells: Biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies","volume":"181","author":"Maddur","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.42.5.1092","article-title":"CD4+ T-epitope repertoire on the human acetylcholine receptor alpha subunit in severe myasthenia gravis: A study with synthetic peptides","volume":"42","author":"Manfredi","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.035_bib52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.035_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"Journal of Neuroimmunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1212\/WNL.0b013e3181d31e47","article-title":"Undiminished regulatory T cells in the thymus of patients with myasthenia gravis","volume":"74","author":"Matsui","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunological Reviews"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.035_bib56","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and lambert-eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2025.04.035_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106864","article-title":"Whole-exome sequencing and human leukocyte antigen analysis in familial myasthenia gravis with thymoma: Case report and literature review","volume":"208","author":"Nakamura","year":"2021","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/bs.irn.2025.04.035_bib58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1749-6632.1995.tb55854.x","article-title":"Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory","volume":"764","author":"Nemazee","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.035_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0896-8411(89)90121-2","article-title":"T-cell reactivity in myasthenia gravis","volume":"2","author":"Newsom-Davis","year":"1989","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.035_bib60","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","author":"Nguyen","year":"2024","journal-title":"Nature Medicine"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.035_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib62","first-page":"S115","article-title":"The myasthenia gravis inebilizumab trial (Mint): Design of randomized, placebo-controlled phase 3 study of an anti-Cd19 monoclonal antibody in generalized myasthenia gravis","volume":"62","author":"Nowak","year":"2020","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.035_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 trial of inebilizumab in generalized myasthenia gravis","author":"Nowak","year":"2025","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.035_bib64","article-title":"B cell targeted treatment in myasthenia gravis A phase 2 trial of rituximab in MG: Topline results","author":"Nowak","year":"2018","journal-title":"AAN"},{"key":"10.1016\/bs.irn.2025.04.035_bib65","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG study","author":"Nowak","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: A retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1085","article-title":"Negative selection--clearing out the bad apples from the T-cell repertoire","volume":"3","author":"Palmer","year":"2003","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib68","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"Journal of Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.035_bib69","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurology"},{"issue":"19","key":"10.1016\/bs.irn.2025.04.035_bib70","article-title":"Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis","volume":"87","author":"Protti","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib71","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4049\/jimmunol.1501843","article-title":"Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood","volume":"196","author":"Quach","year":"2016","journal-title":"Journal of Immunology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.035_bib72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: Diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/bs.irn.2025.04.035_bib73","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1749-6632.1995.tb55853.x","article-title":"Origins of anti-DNA antibodies and their implications for B-cell tolerance","volume":"764","author":"Radic","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Research and Human Genetics: the Official Journal of the International Society for Twin Studies"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.035_bib76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib77","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib78","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T cell anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-065X.2010.00917.x","article-title":"The power and the promise of restimulation-induced cell death in human immune diseases","volume":"236","author":"Snow","year":"2010","journal-title":"Immunological Reviews"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/jtd.2016.03.03","article-title":"Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma","volume":"8","author":"Song","year":"2016","journal-title":"Journal of Thoracic Disease"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"17","key":"10.1016\/bs.irn.2025.04.035_bib83","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib85","doi-asserted-by":"crossref","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10.1016\/bs.irn.2025.04.035_bib86","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","author":"Takata","year":"2019","journal-title":"American Society for Clinical Investigation"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clinical Immunology (Orlando, Fla. )"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib88","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clinical and Experimental Immunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib90","first-page":"415","article-title":"Inhibition of complement activation by IgG4 antibodies","volume":"64","author":"van der Zee","year":"1986","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib91","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.035_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"Journal of Autoimmunity"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib93","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02691-3","article-title":"Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis","volume":"20","author":"Villegas","year":"2023","journal-title":"Journal of Neuroinflammation"},{"issue":"23","key":"10.1016\/bs.irn.2025.04.035_bib94","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"European Journal of Biochemistry \/ FEBS"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib95","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.035_bib96","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.52.3.484","article-title":"Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: Role of CD4+ and CD8+ cells","volume":"52","author":"Wang","year":"1999","journal-title":"Neurology"},{"issue":"5638","key":"10.1016\/bs.irn.2025.04.035_bib97","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science (New York, N. Y. )"},{"key":"10.1016\/bs.irn.2025.04.035_bib98","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.035_bib99","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006957","article-title":"T-Cell tolerance: Central and peripheral","volume":"4","author":"Xing","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.035_bib100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"Journal of Clinical Immunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2025.04.035_bib102","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2013","journal-title":"Journal of Autoimmunity"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib103","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.035_bib104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fneur.2017.00034","article-title":"B10 cell frequencies and suppressive capacity in myasthenia gravis are associated with disease severity","volume":"8","author":"Yi","year":"2017","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.035_bib105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0165-5728(94)90044-2","article-title":"Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells","volume":"50","author":"Yi","year":"1994","journal-title":"Journal of Neuroimmunology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.035_bib106","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/acn3.645","article-title":"Regulatory B cells in myasthenia gravis are differentially affected by therapies","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123546","article-title":"Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK","volume":"10","author":"Yilmaz","year":"2015","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib108","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000012463","article-title":"Characterization of LRP4\/Agrin antibodies from a patient with myasthenia gravis","volume":"97","author":"Yu","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.035_bib109","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.035_bib110","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"Journal of Immunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.035_bib111","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.cr.7290345","article-title":"The role of apoptosis in the development and function of T lymphocytes","volume":"15","author":"Zhang","year":"2005","journal-title":"Cell Research"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.035_bib112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: Central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/bs.irn.2025.04.035_bib113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.035_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686466","article-title":"Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders","volume":"12","author":"Zografou","year":"2021","journal-title":"Frontiers in Immunology"}],"container-title":["International Review of Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T11:41:32Z","timestamp":1748173292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":114,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.035","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}